Genmab — November 2020

[E_L]

i thought it was interesting to hear Jan speak about AbbVie and also their next generation ADC technology. Wondering if we should put this in context with their decision on ADCT/ Cami T

[E_L]

of which they did not speak negatively by the way, Cami came up as another potential future revenue

[E_L]

Jan mentioned 5 Epco trials, where i only see 4, not sure if that was an error or we should see one very soon?

[Solsen]

He also said that the big epco ph 1/2 trial were inrolling in many cohort/indications which could lead to accelerated approval....

[E_L]

yes, it seems ASH could be more interesting as i had anticipated if they can reveal enough data on epco...

[E_L]

they also made me think about Enapotamab again , it has the same warhead as Tisotumab, i wonder if it could be a candidate for another 50:50 with Seagen. They already get a royalty.

[Solsen]

All points at a dead candidate in Enapotamab, I belive.

[E_L]

if they still see sufficient potential, such a partnership could be an elegant solution. We'll find out soon...

[Solsen]

Hope so

[E_L]

Jan said he had a fireside chat toghether with JNJ's Paul Stoffels 2 days ago, has anyone seen that?

[Helge_LarsenPI-redaktør]

We are pleased to share our financial
calendar for 2021. For details, visit https://ir.genmab.com/financial-cale

[E_L]

the new kid on the block with a new Ph2 trial -A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma https://www.clinicaltrials.gov/ct2/show/NCT04634552?term=NCT04634552&draw=2&rank=1

[StockBull]

Wall street targets https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88705_tipranks.JPG

[Klarussen]

@StockBull, ja, spændende om det er herfra vi skal opad på retracement. Holder nu krudtet tørt indtil videre.

[AaBforever]

Pas nu på du ikke bare venter på Godot..;-)

[E_L]

Blood - A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys https://ash.confex.com/ash/2020/webprogram/Paper137006.html

[E_L]

Novo Q3 "Regarding the FVIII-mimicking antibody project, Mim8, we have despite a COVID-19 related period of delay in phase 1, caught up with the timelines and are now in phase 2 in hemophilia patients with or without inhibitors, hemophilia A patients."

[Klarussen]

Just a moment...

(www.proinvestor.com)

[Klarussen]

Stoxx: Nu skal de europæiske healthcare aktier holde stand, ellers ….

[Helge_LarsenPI-redaktør]

Det er bare et gæt Klarussen.